Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Clarithromycin + furazolidone regimen with or without Pyloshot for refractory Helicobacter pylori infection
IRCT20230827059273N1Phase 3Completed
- Sponsor
- Ardabil University of Medical Sciences
- Start
- Mar 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of clarithromycin and furazolidone in Helicobacter pylori infection (2 arms), sponsored by Ardabil University of Medical Sciences. Primary endpoint: Helicobacter pylori eradication rate. Started Mar 2024; status: completed.
02
Drugs
clarithromycinfurazolidone
03
Conditions
Helicobacter pylori infection
Beyond the preview
Go deeper on IRCT20230827059273N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20230827059273N1.